From DCAT Value Chain Insights (VCI)
Valeant Pharmaceuticals International has named Christina Ackermann as executive vice president and general counsel, reporting directly to Joseph C. Papa, chief executive officer and chairman of the board. Ms. Ackermann is an experienced counselor with pharmaceutical industry experience. For the past 14 years, she has served in various legal roles at the Novartis group of companies, most recently as senior vice president and general counsel for Alcon, where she was responsible for the legal, intellectual property and compliance functions. Ms. Ackermann succeeds Robert Chai-Onn, who will be leaving Valeant after a transition period.
Also, Scott Hirsch joins Valeant as senior vice president, business strategy and communications. Mr. Hirsch is an investment professional with knowledge of the specialty pharmaceutical industry. He joins Valeant from Citadel Investment Group, where he oversaw equity investments and risk management decisions within the Health Care sector at Surveyor Capital. Earlier in his career, he was in the investment banking group of Credit Suisse as the lead equity research analyst covering specialty pharmaceuticals and generics.
Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT).
Learn more and sign up to receive a complimentary subscription